MDx NEXT 2012

Subscriber Login

Login
G2IQ Logo
G2 Intelligence
  • Lifepoint Ad
  • LIR Sample Issue Ad
Ezine Sign-up
FREE e-zine for diagnostics pros. Subscribe now to this weekly email featuring G2's proprietary findings.
Subscribe

Upcoming G2 Events

MDx NEXT 2012
April 17-19, 2012
Fairmont Copley Plaza
Boston, MA
Lab Outreach 2012
June 6-8, 2012
Paris Las Vegas
Las Vegas, NV
Lab Institute 2012
October 10-12, 2012
Crystal Gateway Marriot
Arlington, VA

Diagnostics Market Analysis and Trends

Events

April 17-19, 2012 - Boston, MA

Features & Analysis

»2011 a Mixed Year for Diagnostics Industry
The year 2011 was a tumultuous one for the diagnostics industry. Some companies were able to thrive with record revenue growth and an increasingly promising pipeline, while others saw revenues plummet and stock prices tumble under the pressure of global economic uncertainties.

Laboratory Business Strategy and Operations

Events

June 6-8, 2012 - Las Vegas, NV

Features & Analysis

»FTC Approves LabCorp’s Acquisition of Orchid Cellmark But With Conditions
Following numerous extensions of its tender offer, LabCorp (Burlington, N.C.) in early December finally received approval from the Federal Trade Commission (FTC) to acquire Orchid Cellmark, but only under certain conditions.

Diagnostics Regulation, Compliance and Risk

Events

Wednesday, March 7, 2012 2:00 p.m. - 3:30 p.m. ET

Features & Analysis

»Congress Defers Medicare Physician Pay Cut for Two Months; Last-Minute Deal Also Extends Pathology Grandfather Protection
In last-minute maneuverings, Congressional lawmakers Dec. 23 approved an amended version of payroll tax legislation that also would defer for two months a Medicare pay cut for physicians that had been due to be implemented Jan. 1.
Creatign a Value Driven Lab

Lab and Pathology Free Newsletter
G2's FREE, weekly email gives you access to G2 market analysis, regulatory changes, M&A activity, leadership moves and more on the diagnostics industry. Recent articles include:

  • »Gen-Probe Gets FDA Nod for PCA3 Prostate Cancer Assay
    Stephanie Murg, Managing Director, G2 Intelligence
    The Progensa PCA3 assay is the first urine-based molecular test to help determine the need for repeat prostate biopsies.
  • »Delay Announced for ICD-10 Compliance Date
    Jim Curren, National Intelligence Report
    Health and Human Services secretary Kathleen Sebelius announced on Feb. 16 that HHS will initiate a process to postpone the date by which health care entities covered under the Health Insurance Portability and Accountability Act (HIPAA) will have to comply with use of the International Classification of Diseases, 10th Edition diagnosis and procedure codes (ICD-10).
  • »Medicare Lab Fees Cut to Pay for Physician Fee Fix
    Jim Curren, Editor, National Intelligence Report
    At press time, Congress just passed, and the President is expected to sign, conference committee legislation that would cut Medicare lab fees by $2.7 billion over 10 years to help pay for another short-term Medicare physician fee fix.
More Insider Subscribe
Lab and Pathology Wire Logo

G2's FREE, daily email service brings you up-to-the-minute lab and diagnostics industry news from from across the spectrum of providers.
Subscribe
  • Medicare Tower Ad
|
»